// EntheoBlog

Archive for 29 June 2006

29 June

createOption('InternetAddress','Automatically create links for internet addresses ?','yesno','yes'); $this->createOption('NewWindow','Open links in a new window?','yesno','no'); $this->createOption('MailAddress','Automatically create links for mail addresses ?','yesno','yes'); $this->createOption('RewriteMailAddress','Rewrite mail addresses with [at] and [dot]?','yesno','yes'); $this->createOption('at','Placeholder for @','text','[at]'); $this->createOption('dot','Placeholder for .','text','[dot]'); } function getEventList() { return array('PreItem', 'PreComment'); } function Treatment($_text) { global $CONF, $blog; if ($this->getOption('NewWindow') == 'yes') { $nw="onclick=\"javascript:window.open(this.href, '_blank'); return false;\""; } if ($this->getOption('InternetAddress') == 'yes') { $_text = preg_replace('/(\s)([http|https|ftp|file]+:\/\/[a-zA-Z0-9_?=&%;+-.\/]*)/si','\1\2',$_text); $_text = preg_replace('/(\s)(www\.[a-zA-Z0-9_?=&%;+-.\/]*)/si','\1\2',$_text); } $at = $this->getOption('at'); $dot = $this->getOption('dot'); if ($this->getOption('MailAddress') == 'yes') { if ($this->getOption('RewriteMailAddress') == 'no') { $_text = preg_replace('/(\s)([a-zA-Z0-9\._-]+@[a-zA-Z0-9\._-]+\.[a-zA-Z]{2,5})/s','\1\2',$_text); } else { $_text = preg_replace('/(\s)([a-zA-Z0-9\._-]+)@([a-zA-Z0-9\._-]+)\.([a-zA-Z]{2,5})/s','\1\2'.$at.'\3'.$dot.'\4',$_text); } } if ($this->getOption('MailAddress') == 'no' && $this->getOption('RewriteMailAddress') == 'yes'){ $_text = preg_replace('/(\s)([a-zA-Z0-9\._-]+)@([a-zA-Z0-9\._-]+)\.([a-zA-Z]{2,5})/s','\1\2'.$at.'\3'.$dot.'\4',$_text); } return $_text; } function event_PreItem($_data) { $_data[item]->body = $this->Treatment($_data[item]->body); $_data[item]->more = $this->Treatment($_data[item]->more); } function event_PreComment($_data) { $_data['comment']['body'] = $this->Treatment($_data['comment']['body']); } function supportsFeature ($what) { switch ($what) { case 'SqlTablePrefix': return 1; default: return 0; } } } ?>

Bremelanotide (PT-141) - aus Wikipedia

Es kommen immer mal wieder Fragen zu solchen Sachen, hier also ein weiterer Eintrag aus der Kategorie Spickzettel:

"Bremelanotide (formerly PT-141) is the generic term for a new medication for use in treating sexual dysfunction in men (erectile dysfunction or impotence) as well as sexual dysfunction in women (sexual arousal disorder). It seems to be the first real aphrodisiac. Unlike Viagra and other related medications, it does not act upon the vascular system, but directly increases sexual desire. Bremelanotide is a spray introduced nasally.

Originally, the peptide Melanotan II that bremelanotide was developed from was tested as a sunless tanning agent. In initial testing, Melanotan II did induce tanning but additionally caused sexual arousal and spontaneous erections as unexpected side effects in eight out of the ten original male volunteer test subjects. In clinical studies, bremelanotide has been shown to be effective in treating male sexual and erectile dysfunction as well as female sexual dysfunction. It is currently being tested by Palatin Technologies."

Bremelanotide - Wikipedia, the free encyclopedia

[Den ganzen Text lesen] -  Karma: 44 [+/-]
Geschrieben von harko um 13:43:04 Uhr - Keine Kommentare vorhanden - Keine Trackbacks
Abgelegt unter Entheogene
Einfach Flattrn wenn es gefällt - Danke.